Find out about the risks here
Brar PC, Heksch R, Cossen K, et al
Interestingly, L585 could only be replaced with an amino acid having similar physiochemical properties, including isoleucine, methionine, and valine, without negatively affecting FcRn binding 64
Its listed rate should not rise solely with dose
In addition to many GLP-1-based pharmacotherapies being tested in clinical settings for the treatment of obesity, GLP-1R agonists are successfully used in the clinic to treat type 2 diabetes mellitus (T2DM) and its related complications such as diabetic nephropathy [37, 39, 40]